# US 2023/0414509 A1 · Hydrophobic drugs in organic core high density lipoprotein (hdl) nanoparticles

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2023/0414509 A1
- Document ID: US20230414509A1
- Status: Published application
- Kind: A1
- Application number: 18/032,201
- Filed: 2021-10-22
- Published: 2023-12-28
- Earliest claimed: 2020-10-23
- Assignees: Northwestern University; City of Hope
- Applicants: Northwestern University; City of Hope
- Inventors: Stephen E. Henrich; Jonathan S. Rink; Adam Y. Lin; C. Shad Thaxton; Leo I. Gordon; Sonbinh T. Nguyen; Steven T. Rosen; David Horne; Xu Hannah Zhang
- Web page: https://patentgrep.com/patent/US20230414509A1

## CPC

- A61K 9/1275: Lipoproteins or protein-free species thereof, e.g. chylomicrons; Artificial high-density lipoproteins [HDL], low-density lipoproteins [LDL] or very-low-density lipoproteins [VLDL]; Precursors thereof
- A61K 9/5123: {Organic compounds, e.g. fats, sugars}
- A61K 31/437: the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
- A61K 47/544: {Phospholipids}
- A61K 47/549: {Sugars, nucleosides, nucleotides or nucleic acids}
- A61K 47/6917: {the form being a lipoprotein vesicle, e.g. HDL or LDL proteins}
- A61P 35/00: Antineoplastic agents
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Disclosed herein are high-density lipoprotein-like nanoparticles (HDL-NP) having a soft material core (e.g., a lipid-conjugated inorganic core) associated with hydrophobic therapeutic agents. In some embodiments, the HDL-NPs are targeted to scavenger receptor type B1 (SR-B1). In some embodiments, the hydrophobic therapeutic agents are chemotherapeutic agents. Also disclosed herein are methods for treating disorders such as cancer with the HDL-NPs.

## Claims

### Claim 1

A high-density lipoprotein nanoparticle (HDL-NP) comprising:
(a) an organic core, wherein the core comprises a hydrophobic phospholipid conjugated scaffold (PL4); and
(b) a shell surrounding and attached to the core; and
(c) a hydrophobic therapeutic agent associated with one or more of the organic core or shell.

### Claim 2 (depends on 1)

The HDL-NP of claim 1, wherein the HDL-NP further comprises an apolipoprotein.

### Claim 3 (depends on 2)

The HDL-NP of claim 2, wherein the apolipoprotein is apolipoprotein A-I (Apo-I).

### Claim 4 (depends on 2)

The HDL-NP of
claim 2, wherein the hydrophobic therapeutic agent is associated to the organic core, shell, or apolipoprotein non-covalently or through hydrophobic interactions.

### Claim at position 5

5-6. (canceled)

### Claim 7 (depends on 1)

The HDL-NP of claim 1, wherein the shell is a lipid shell, wherein the lipid shell is a lipid monolayer or a lipid bilayer.

### Claim 8 (depends on 1)

The HDL-NP of claim 1, wherein the PL4 comprises a headgroup-modified phospholipid.

### Claim 9 (depends on 8)

The HDL-NP of claim 8, wherein the headgroup-modified phospholipid comprises a ring-strained alkyne, 1,2-dipalmitoyl-sn-glycero-3-phosphoethan-olamine-N-dibenzocyclooctyl.

### Claim 10 (depends on 1)

The HDL-NP of claims 1, wherein the organic core scaffold comprises an amphiphilic DNA-linked small molecule-phospholipid conjugate (DNA-PL4).

### Claim 11 (depends on 1)

The HDL-NP of claim 1, wherein the HDL-NP has a diameter of about 5-30 nm.

### Claim 12 (depends on 1)

The HDL-NP of claim 1, wherein the HDL-NP has a zeta potential closer to human HDL than a synthetic HDL nanoparticle with a gold core.

### Claim at position 12

13-14. (canceled)

### Claim 15 (depends on 1)

The HDL-NP of claim 1, wherein the hydrophobic therapeutic agent has a partition coefficient (P) of greater than or equal to 0 (log P≥0).

### Claim at position 14

16-19. (canceled)

### Claim 20 (depends on 1)

The HDL-NP of claim 1, wherein the hydrophobic therapeutic agent is an anti-cancer agent.

### Claim at position 16

21-22. (canceled)

### Claim 23 (depends on 1)

The HDL-NP of claim 1, wherein the hydrophobic therapeutic agent comprises PIK75 (F7) (C16H14BrN5O4S·HCl), doxorubicin, vincristine, gemcitabine, paclitaxel, docetaxel, andrographolide, sutent, tamoxifen, or a combination thereof.

### Claim 24

(canceled)

### Claim 25 (depends on 1)

The HDL-NP of claim 1, wherein the hydrophobic therapeutic agent has a structure of Formula (I) (CAS No. 372196-77-5).

### Claim 26 (depends on 20)

A pharmaceutical composition comprising the HDL-NP of claim 20.

### Claim 27 (depends on 26)

A method of delivering a hydrophobic therapeutic agent to a cell comprising surface receptor scavenger receptor type B1 (SR-B1) in a subject, the method comprising administering to a subject an effective amount of the composition of claim 26.

### Claim 28 (depends on 26)

A method for treating a cancer, the method comprising administering to a subject having a cancer the composition of claim 26 in an effective amount to treat the cancer.

### Claim 29

(canceled)

### Claim 30 (depends on 28)

The method of claim 28, wherein the subject is a human.

### Claim 31

(canceled)

### Claim 32 (depends on 30)

The method of claim 30, wherein the subject has one or more of renal cancer, chronic myeloid leukemia (CML), multiple myeloma (MM), adult acute myeloid leukemia (AML), acute lymphocytic leukemia (ALL), cutaneous T cell lymphoma (CTCL), melanoma, ovarian cancer, breast cancer, gastrointestinal malignancies, brain tumors, prostate cancer, and colon cancer.

### Claim at position 27

33-34. (canceled)

### Claim 35 (depends on 30)

The method of claim 30, wherein the effective amount of the hydrophobic therapeutic agent necessary to treat the subject having cancer is decreased relative to a control subject being treated with the same hydrophobic therapeutic agent delivered in the absence of an HDL-NP.

### Claim 36

(canceled)

### Claim 37 (depends on 30)

The method of claim 30, wherein the composition causes reduced cytotoxicity of non-cancerous cells in the subject and/or reduced symptoms, relative to a standard-of-care treatment.

### Claim 38

(canceled)
